Nanobodies targeting claudin 18.2 and uses thereof

CN120484124BActive Publication Date: 2026-05-29HARBIN MEDICAL UNIVERSITY
View PDF 2 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
HARBIN MEDICAL UNIVERSITY
Filing Date
2025-05-16
Publication Date
2026-05-29

Smart Images

  • Figure CN120484124B_ABST
    Figure CN120484124B_ABST
Patent Text Reader

Abstract

The application discloses a nanobody targeting Claudin 18.2 and an application thereof, and belongs to the technical field of molecular biology. In view of the unique advantages of the nanobody in the prior art, the application provides a nanobody targeting Claudin 18.2, wherein the amino acid sequence of the nanobody is shown as SEQ ID NO. 1; the nanobody has strong affinity to 293T-Claudin 18.2 positive cells and can be combined with the Claudin 18.2 protein expressed on the cell surface. The nanobody targeting Claudin 18.2 provided by the application can be prepared by large-scale expression of an in-vitro engineering bacterium, can be applied to preparation of a protein detection antibody or a therapeutic antibody, can be used for in-vitro and in-vivo detection of tumor tissues expressing Claudin 18.2, and has important commercial value in clinical disease diagnosis and treatment.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Anti-CLD18A2 single-domain antibody

    CN114222761A

  • Nanometer antibody targeting Claudin18.2 and application thereof

    CN115403671A